For over a decade, ex vivo platforms have shaped the foundational breakthroughs in cell and gene therapy. CAR-T therapies demonstrated that engineered cells can deliver transformative benefits, and ex vivo gene editing of hematopoietic stem cells paved the way for treating blood and immunological disorders. These successes built the industry. They also exposed the field’s structural limitations: long manufacturing cycles, the requirement for conditioning chemotherapy, high costs, and the difficulties of scaling beyond specialized centers.
These constraints are no longer manageable side notes. They represent real commercial and clinical barriers, which is precisely why investor attention and pharma acquisitions have shifted dramatically toward in vivo approaches. The past 18 months have altered the competitive landscape at a pace that ex vivo companies cannot ignore.
The companies winning funding and M&A attention are the ones that can articulate a credible in vivo strategy. If you are developing ex vivo therapies today, the question is not whether in vivo will affect your future; the question is whether you are positioning yourself to compete in it.
The 5th In Vivo Cell Engineering & Gene Editing Summit is the meeting designed to help you take that step with confidence.
Why the Shift to In Vivo Matters for Ex Vivo Developers
Investors Have Already Signalled Their Direction of Travel
The investment shift is explicit. Pharma committed over 7.3 billion dollars to in vivo acquisitions in the past year. These deals include major buyouts like AbbVie’s acquisition of Capstan Therapeutics and AstraZeneca’s acquisition of Orbital Therapeutics, both centered on in vivo CAR-T programs. Companies that want to remain competitive in the cell and gene space now need some form of in vivo capability to be viewed as commercially viable for future pipelines.
For ex vivo companies navigating a more competitive funding environment, this is a direct signal. Investors are prioritizing pipelines that can demonstrate clinical translation with fewer manufacturing bottlenecks and clearer paths to scalability. In vivo approaches offer exactly that.
Attending the summit provides access to the clearest articulation of what investors expect next through the dedicated Search, Evaluation, and Investment Panel, presented by Kite Pharma, AbbVie, AstraZeneca, and Eli Lilly, which reviews the evidence and value inflection points that shape investment decisions for in vivo programs.
Clinical Momentum Is Accelerating Faster Than Anticipated
The last year delivered the first in vivo human signals across multiple indications. Early data from in vivo CAR-T programs and emerging proof points in autoimmune and solid tumor indications are shifting expectations around what is clinically feasible.
For ex vivo companies, clinical data drives credibility; understanding how in vivo developers design their trials, manage safety, and interpret translational signals is essential for benchmarking your own trajectory.
Key sessions at the summit will unpack:
- Clinical reflections and trial design strategies shared by biopharma leaders from companies like CREATE Medicines and Sana Biotechnology
- Emerging NHP and early human data from targeted LNP programs and in vivo immunotherapy platforms
- Adaptive cohort design, monitoring frameworks, and biomarker‑informed dose strategies that are shaping the next generation of studies
These sessions give ex vivo developers a detailed understanding of how to build credible future clinical strategies that align with investor expectations.
Where Ex Vivo Companies Fit in the Emerging Landscape
Ex vivo teams bring a deep understanding of cell engineering, translational immunology, and regulated manufacturing frameworks, which remain invaluable. What has changed is the baseline of what investors and pharma partners expect.
For ex vivo teams exploring expansion into in vivo, this is an invaluable opportunity to:
- Hear how peers transitioned into in vivo
- Understand what pitfalls they encountered
- Gain visibility on delivery and editing decisions among competitors
Build relationships with potential partners before they are acquired
What Ex Vivo Teams Will Learn at the Summit
1. Delivery & Targeting Innovations That Can Inform Your Next Platform Decision
The program features sessions on targeted LNPs, viral vectors, enveloped delivery vehicles, lentiviral pseudotypes, and DNA‑based nanoparticle systems. Speakers from Innorna, Beam Therapeutics, GigaMune, and others will present data that clarifies how to select and optimize delivery vehicles for specific indications and payloads.
Even if your current pipeline is ex vivo, knowing where delivery technologies are going helps you strategically plan your next-generation platforms.
2. Benchmarks For Clinical Readiness In In Vivo
The emergence of early clinical data means the field is moving toward clearer expectations for safety, tolerability, and early signals of activity. Presenters from iECURE, Asgard Therapeutics, and others will unpack real translational and clinical datasets that allow you to calibrate your internal decision-making frameworks.
3. How to Position Your Company for Future Partnerships & Acquisitions
With pharma leaders like AbbVie, Kite Pharma, AstraZeneca, and Eli Lilly speaking across the program, you gain direct insight into:
- How pharma evaluates in vivo assets
- What constitutes a meaningful data package
- How corporate strategy teams prioritize investment
- What early signals trigger partnership interest
This level of access is rare and directly valuable for ex vivo companies considering expansion or future exits.
Explore the Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.